Ahmed Mohammad Mohi Eldin Ali

Treatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma / تحديد طريقة علاج حالات أورام الغدد الليمفاوية غير الهودجكن ذات الخلايا الكبيرة حسب كل حالة مرضية Ahmed Mohammad Mohi Eldin Ali ; Supervised Hussain Mostafa Khaled , Nadia Mahmoud Mokhtar , Foaad Mohammad AbuTaleb - Cairo : Ahmed Mohammad Mohi Eldin Ali , 2012 - 175 P. : charts ; 25cm

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical

CD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining



CD20-positive diffuse large B-cell lymphoma R-CHOP Rituximab